top of page
LATEST NEWS
Stem Cell Breakthrough Lets Paralyzed Patient Stand Again
Japanese researchers restored movement in a paralyzed man using reprogrammed stem cells injected into his spinal-cord injury. The treatment, tested in four patients, helped one man stand independently and another regain limb movement, offering early evidence that iPS cell therapies may support neural repair and future paralysis treatments.
4 days ago
Scientists Cure Type 1 Diabetes in Mice Using a Gentle Immune System “Reset”
Stanford Medicine researchers cured Type 1 diabetes in mice using a gentle immune-reset approach that combines donor blood stem cells and pancreatic islet transplants. The method prevented autoimmunity, required no immunosuppressive drugs, and may pave the way for future treatments for diabetes and other autoimmune diseases.
5 days ago
Orforglipron Weight-Loss Pill Trial Results: Eli Lilly Reports 12.4% Body Weight Reduction, Shares Fall 15%
Eli Lilly’s once-daily oral weight-loss pill, orforglipron, helped patients lose 12.4% of their body weight in a Phase 3 trial, but fell short of rival Wegovy’s results. The announcement sent Lilly shares down 15%, the company’s steepest drop in 25 years, despite meeting all primary and secondary endpoints and showing improvements in heart health markers.
Aug 11
LEARN MORE
GENE TECH TIMES
The Future Has Arrived
FDA Rejects Ultragenyx's Gene Therapy for Rare Disease - Sanfilippo Syndrome
Ultragenyx has received an FDA rejection for its experimental gene therapy targeting Sanfilippo syndrome, a rare and fatal pediatric neurodegenerative disorder. The FDA cited concerns over efficacy data, delaying approval for the treatment. The decision is a major setback for families awaiting a one-time gene therapy option to address the root cause of this rare disease. Ultragenyx plans to work with regulators to resolve the issues and continue advancing its gene therapy pip
Jul 16
bottom of page